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Introduction
Cell-free DNA (cf-DNA)-based liquid biopsy is emerging as a noninvasive method to characterize genomic aberrations in cancer. Detecting or tracing variations in cf-DNA provides a promising method of guiding targeted therapy [1, 2] , monitoring tumor burden and predicting therapeutic effects [3, 4] for various types of cancers. The reappearance of tumor-specific mutations in the cf-DNA of patients after radical surgery accurately predicts tumor recurrence 2-15 months earlier than medical imaging [4] . However, detecting early-stage cancers using cf-DNA remains challenging, as circulating tumor DNA (ct-DNA) accounts for a fairly low proportion of cf-DNA (typically 1% or less) [2] .
Somatic mutations can arise and accumulate to hundreds or a few thousand in number over a lifetime in normal cells [5, 6] . In recent years, several studies have described somatic clonal aberrations in various normal human tissues [6, 7] , including in the whole blood of a minor portion (1%-3%) of healthy individuals and cancer patients without hematologic malignancies [7, 8] . Recently, a study identified clonal hematopoietic cells harboring acute myeloid leukemia (AML)-associated mutations in 19 of the 20 healthy adults, suggesting prevalent clonal expansion in the hematopoietic system [9] . However, the somatic mutations in premalignant clones may be released into cf-DNA after cell apoptosis, affecting the biological background in cf-DNA, which has not been comprehensively described and may be a source of the discordance observed between tumor tissue and cf-DNA analyses reported broadly in the literature [10] .
With a general next-generation sequencing (NGS) procedure, PCR, and sequencing errors inevitably introduce base mismatches (>0.1%) [2, 11] and hinder the accurate identification of low-frequency mutations. To achieve a high accuracy for mutation detection in cf-DNA, it is necessary to reduce experimental artifacts while assessing the biological background. To date, several studies have made considerable progress using protocols based on barcoding single-strand DNA fragments and have reported an ultralow base error rate ( 0.001%) in genomic DNA [11, 12] . However, the best performance was achieved by duplex sequencing, which utilized the information from complementary strands of DNA molecules to correct errors and claimed an unprecedented low base error rate (<10 À9 ) [13] . In this study, to detect low-frequency somatic mutations and to reveal the biological background of cf-DNA, we applied our endogenous barcoding duplex method on ultradeep target sequencing data from 259 cancer-free individuals.
Materials and methods

Sample set
Peripheral blood samples (10 ml) of 259 cancer-free individuals and 16 cancer patients were collected with the permission of the Ethics Committee of BGI. Clinical information was available for 205 cancer-free individuals according to their privacy requests (supplementary Table S1 , available at Annals of Oncology online). Cf-DNA and blood cell DNA were extracted (supplementary Table S2 , available at Annals of Oncology online) and sequenced via Illumina HiSeq2000/2500 after capture by two target gene panels (panels V1 and V2; supplementary Table S3 , available at Annals of Oncology online). Among the 259 cancer-free individuals, 202 were captured by panel V1, which included 1.7 megabases of frequently mutated regions in 508 cancer-related genes, while the other 57 samples were captured by another target panel covering 1.6 megabases (panel V2) on 559 cancer-related genes, which shared 1.2 megabases with panel V1.
Duplex sequencing and mutation detection
Instead of inserting unique identifiers on the adapter as described in the duplex sequencing method [13] , we used the 12 base sequences at both ends of the DNA fragment as endogenous molecular barcodes, which were used to sort and degenerate duplication families into duplex consensus sequences (DCSs) (supplementary Figure S1 , available at Annals of Oncology online). Consistent with an exogenous duplex method, a low library preparation efficiency (6% of DNA templates were transformed into DCS) was observed [14] . However, the loss of library complexity was mainly attributable to the conventional NGS adapter ligation step rather than a requirement of DCSs (supplementary Methods, available at Annals of Oncology online). The proportion of duplication families to form DCSs (DCS efficiency) was $39% across samples, indicating a 61% loss of library complexity compared with the conventional NGS protocol (supplementary Figure S2 , available at Annals of Oncology online). The DCS efficiency is mainly determined by the duplication family size and would increase with more sequencing data, as shown by the DCS efficiencies of 59.5% and 93.9% for duplication families with three and seven duplicates, respectively (supplementary Figure S3A and B, available at Annals of Oncology online). The DCSs were then aligned to the hg19 reference genome before the detection and filtration of single-nucleotide variations (SNVs) and indels using a local pipeline. The details of duplex sequencing and data analysis are provided in the supplementary Methods, available at Annals of Oncology online.
Results
Evaluation of the detection power by spike-in experiments
The detection power of our method was evaluated by a twohuman plasma DNA blend sample (at a ratio of 1 : 200), which was captured using panel V1 and sequenced with a DCS depth of 532Â. Forty-nine homozygous and 226 heterozygous 'spike-in' mutations with variant allele frequencies (VAFs) of 0.5% and 0.25%, respectively, were used to measure the sensitivity and specificity of our method. Ultimately, we obtained a sensitivity of 80% (39/49) and a specificity of 100% for homozygous 'spike-in' mutations and a sensitivity of 35% (80/226) and a specificity of 100% for heterozygous 'spike-in' mutations (supplementary Table S4 , available at Annals of Oncology online), indicating zero false-positive calls in the entire target region. The base error rates of DCSs were dramatically reduced by three orders of magnitude compared with the original HiSeq2000/2500 sequencing bases with quality scores above 30 (supplementary Figure S2A and B, available at Annals of Oncology online), especially for C>T and G>T substitutions, the dominant types of artificial errors that can be induced by DNA damage such as deamination and oxidation, or polymerase errors occurring during library amplification [14] .
Detection and validation of mutations in cf-DNA of normal individuals
Cf-DNA was sequenced with an average original depth of 6200Â in 259 normal individuals. Using our endogenous molecular barcoding method, a median DCS depth of 380Â (120Â to 650Â) was obtained for 259 samples. The base error rate of DCSs was evaluated to be $2 Â 10 À7 and showed no correlation with DCS depths (supplementary Figure S5 , available at Annals of Oncology online). The peripheral blood cell DNA was sequenced with an average original depth of 406Â for comparison for all individuals. To eliminate false positives, only mismatches supported by at least two disparate DCSs were considered for further analysis. For indels, not only those detected in one DCS but also supported by sequencing reads in the corresponding blood cell DNA were retained. Mutations located outside of coding regions were excluded.
In total, 329 mutations predicted to change proteins, including 311 nonsynonymous SNVs and 18 indels, and another 46 synonymous SNVs, were identified in 164 samples. Of all samples, 60% (155/259) presented at least one nonsynonymous SNV or indel. For SNVs, 57% and 18% were C>T transitions and T>C transitions, respectively ( Figure 1A ). The mutational signature mostly correlated with Signature 1B, reported by Alexandrov et al. [15] (R ¼ 0.73), which corresponded to the aging process. As expected, among the 202 samples whose ages are known, the mutation numbers were significantly correlated with older age (R ¼ 0.41, P < 10
À8
; Figure 1B) . However, no significant difference was found between males and females or between those with and those without a family history of cancer (supplementary Figure S6 , available at Annals of Oncology online). Interestingly, 66% (219/329) of all nonsynonymous mutations were also supported by at least one read (sequencing quality !30) in the corresponding blood cell DNA ( Figure 1C) , and for mutations with VAF >1%, this ratio increased to 86% (75/87), indicating the hemopoietic origin of the majority of these mutations. In addition, only 10 and 8 mutations showed significantly (P < 0.05, Fisher's exact test) higher and lower VAFs in cf-DNA than in blood cell DNA, respectively, in line with the expected random occurrence (385 Â 0.05 ¼ 19), indicating similar VAFs of these mutations in cf-DNA and blood cell DNA.
Overall, nonsynonymous mutations were detected in 166 genes (Figure 2; supplementary Table S5 , available at Annals of Oncology online). The most frequently mutated gene was DNMT3A (68 mutations in 52 samples), in which 93.5% (43/46) of missense mutations were located in the Mtase domain, similar to the results previously reported for myelodysplastic syndrome (MDS) [16] (supplementary Figure S7B , available at Annals of Oncology online). Most of the DNMT3A mutations were different from each other, and all were detected no more than two times except for the recurrent hotspot R882 mutation. The hotspot JAK2-V617F mutation, which was reported to be prevalent in myeloproliferative neoplasms (MPN) [17] , was identified in six samples (supplementary Figure S7D , available at Annals of Oncology online). TET2 and ASXL1 mutations were present in 8 and 6 samples, respectively, and showed significant enrichment in truncating mutations (13/15) (supplementary Figure S7A and C, available at Annals of Oncology online). A hotspot MYD88 L273P mutation was found in one sample, which was also frequently detected in chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL) [18, 19] . Other frequently mutated genes included
Of the detected mutations, 52 were randomly selected for validation by ultradeep sequencing of PCR amplicons (median depth up to 200 000Â) in the cf-DNA library, corresponding blood cell DNA, and as negative controls, in both the cf-DNA and blood cell DNA of another healthy control (age 30 years) and N213, which was absent of these mutations. For the mutations, 66% (33/50) and 80.8% (42/52) showed a VAF that was significantly higher than background errors in the cf-DNA library and the corresponding blood cell DNA, respectively, further confirming the presumption of the hemopoietic origin of these mutations (supplementary Figure S8 and Table S6 , available at Annals of Oncology online). None of these mutations showed a VAF that was significantly higher than the error rate in the healthy control and N213, except for the mutation DNMT3A-V657M, which showed significance in both the cf-DNA and blood cell DNA of N213. Interestingly, we also found one DCS that supported this mutation in the sequencing data of N213, suggesting a true mutation in N213 and some undetected clones with lower VAFs.
Mutation spectrum comparison with hematologic malignancies
Based on the common occurrence of mutations in driver genes of hematologic malignancies in our dataset, we compared the mutation spectrum in our dataset with those in six types of hematologic malignancies that correlated with old age and were prevalent in the population, including AML (n ¼ 200), CLL (n ¼ 160), MPN (n ¼ 151), MDS (n ¼ 150), DLBCL (n ¼ 94), and follicular lymphoma (FL) (n ¼ 100) [16] [17] [18] [19] [20] [21] . Twenty-six of the 166 mutated genes (including 137 of 329 mutations) were reported to be driver genes in at least one of the 6 hematologic malignancies (supplementary Figure S9C , available at Annals of Oncology online). Of samples with higher mutation burdens, a higher proportion was found with at least one mutation in these 26 driver genes (supplementary Figure S9A , available at Annals of Oncology online). DNMT3A mutations showed higher VAFs than did mutations in the other driver genes and the passenger genes of the 6 hematologic malignancies (supplementary Figure S9B , available at Annals of Oncology online). Consistent with the study of blood cell DNA in healthy individuals, and in contrast to the study of hematologic malignancies, hotspot DNMT3A-R882 mutations accounted for only a small portion of total DNMT3A mutations in our sample set, suggesting a weak selectivity of DNMT3A hotspot mutations in healthy individuals. Twelve of the 52 DNMT3A mutated samples exhibited more than one DNMT3A mutation, which was more frequent than those reported in hematologic malignancies [19, 22] and suggested parallel clonal expansion events.
According to our results, mutations of certain epigenetic genes, including DNMT3A, TET2, and ASXL1, were frequently mutated in both hematologic malignancies and cancer-free samples and thus appeared to be early events in hematologic malignancies (supplementary Figure S9C , available at Annals of Oncology online). However, mutations of several other driver genes were prevalent in some hematologic malignancies but absent in healthy individuals, such as NPM1, KRAS/NRAS, FLT3, and CREBBP, are likely to arise in a later stage of carcinogenesis. The frequently mutated genes in our samples were mostly consistent with driver genes of AML, while there were also some genes mainly present in other hematologic malignancies. For example, JAK2 and CHEK2 mutations were mostly identified in MPN, while the XPO1 mutations were almost exclusively found in CLL. Some other frequently mutated genes were specific to lymphomas (DLBCL or FL), such as APC, FANCD2, CARD11, and TNFAIP3, suggesting a mixed cell origin of mutations. TP53 is one of the most frequently mutated genes in AML, CLL, MDS, MPN, and DLBCL, but it was found with only one mutation in our sample set.
Biological background of cf-DNA of normal individuals and cancer patients
The VAFs of mutations between cf-DNA and blood cell DNA were similar and highly correlated (R ¼ 0.87), indicating that cf-DNA is enriched in DNA of hematopoietic origin ( Figure 1C) , consistent with previous studies carried out by the deconvolution of the methylation spectrum in cf-DNA [23] . Other than driver genes of hematologic malignancies, several driver genes of solid tumors were also frequently mutated, such as BOBO2, NAV3, NOTCH2, FAT3, EXT2, ATRX, ERBB4, and ARID2. In total, 125 of the 329 mutations were indexed in the COSMIC database, including mutations in ERBB2 (V480M, T948I) and EGFR (D942Y, R958H), and one mutation each was found in MED12, PDGFRA, and GNAQ. However, these mutations were unlikely to be activating mutations because of their rare presence in cancer patients according to the COSMIC database, implying that they might be passenger mutations in clonal hematopoiesis. Moreover, 60% (115/192) of these presumptive 'passenger mutations' were supported by sequencing reads in blood cell DNA. Such mutations may lead to erroneous conclusions related to diagnosis or medical guidance in liquid biopsy.
The cf-DNA and paired blood cell samples of 16 cancer patients after radical surgery was sequenced and analyzed using the same method. Fifty somatic mutations were identified in the cf-DNA of 12 samples, and 12 of these mutations (in 6 samples) were located in hematologic cancer driver genes (supplementary Table S7 , available at Annals of Oncology online), including 6 in DNMT3A and 1 each in TET2, ASXL, TP53, ATM, BCOR, and TNFRSF14. These data strengthened the conclusion that 'passenger mutations' in clonal hematopoiesis may hamper the accurate identification of tumor-derived mutations. However, for postsurgical minimal residual disease detection, tracking mutations already identified in the primary tumor may overcome this limitation, as the hematopoietic 'passenger mutations' appear to be dispersed across locations and would have a lower probability of being present in patient-specific mutation sites.
We evaluated the effectiveness of distinguishing clonal hematopoietic mutations from cf-DNA using blood cell DNA sequencing as a 'hematopoietic filter' for mutations with VAFs of 1%, 0.3%, 0.1%, 0.03%, and 0.01% (supplementary Methods, available at Annals of Oncology online). However, the results showed that without an error correction model and ultradeep sequencing depth, a 'hematopoietic filter' using a conventional NGS approach was not able to effectively distinguish hematopoietic mutations with a VAF below 0.1%, especially for mutation types with higher sequencing error rates (supplementary Figure  S10 , Tables S8, and S9, available at Annals of Oncology online). For example, requiring a G>T hematopoietic mutation with a VAF of 0.1% to be identified using a 'one-read hematopoietic filter' with a sensitivity !95% would result in a low specificity ( 31.2%) (supplementary Methods, available at Annals of Oncology online). For the 'one-read hematopoietic filter', to simultaneously achieve a sensitivity of 95% and a specificity of 95% for mutations with VAF of 0.1%, 0.03%, and 0.01%, which may be required for early-stage cancer screening, the base error rates should be no more than 1.71 Â 10 À5 , 5.13 Â 10 À6 , and 1.71 Â 10
À6
, respectively. To the best of our knowledge, an error rate no more than 5 Â 10 À6 could only be achieved using the duplex sequencing method, as DNA damage events are not efficiently removed by single-strand-based error correction models.
Discussion
Liquid biopsy provides a noninvasive way to guide targeted therapy and immunotherapy, which may be of particular benefit to those not eligible for surgery or biopsy. The mutations in both targetable and drug-resistance genes and the mutation numbers in a panel are important in terms of clinical usability. Our study revealed that somatic mutations in cf-DNA were prevalent in both middle-aged and older individuals, which underscores the importance of distinguishing between tumor-derived and clonal hemopoietic mutations. Approximately 1.2 nonsynonymous mutations per sample were detected in our target panel of cancer-related genes, and 58.4% appeared to be 'passenger mutations' of hemopoietic clones. These mutations are especially likely to be located in clinical-related tumor suppressor genes, such as APC, ARID2, and PTEN. The prevalence of hematopoietic clone mutations should be even higher in a population with metastatic malignancy, which is usually older than the population sampled here. However, a paucity of hotspot oncogenic variants associated with solid malignancies suggests that biological false positives could be reduced in early screening of solid malignancies by detecting only the hotspot events that are not relevant to clonal hematopoiesis rather than a panel-scale screening.
Duplex sequencing has the lowest error rate, which is crucial for confidently detecting variants. However, the low library preparation efficiency restricts its practicability in liquid biopsy, as clinically practical blood volumes are usually limited. In this study, the DCSs utilize only 6% of DNA templates; therefore constrained the limit of detection of VAF to $0.5%, which is substantially higher than the ct-DNA proportion in early-stage cancers (0.1% or less). As demonstrated in the analytical validation experiment, only 35% of variants at a VAF of 0.25% were detected using DCSs; thus, the true frequencies of variants in cf-DNA would be underestimated. With a higher VAF resolution, not only the number of clonal hematopoietic mutations (supplementary Figure S11 , available at Annals of Oncology online) but also the difficulty in distinguishing them would increase greatly. Sequencing of blood cell DNA as a 'hematopoietic filter' is not always effective, especially for those mutations with low VAFs and few supporting-reads. VAFs in blood cells largely matched those in cf-DNA, suggesting that a 'hematopoietic filter' requires a sequencing depth at least matching that of cf-DNA. Without great sequencing depth, the high possibility of allele dropout events in blood cell DNA could result in false negatives in the 'hematopoietic filter', as in the example of the 34% of cf-DNA mutations that were not supported by reads in blood cell DNA in our study. However, as shown by the low DNA and data utilization rate in duplex sequencing, high sequencing depth is difficult and costly to achieve using error correction sequencing methods, and without error correction methods, true cancer-derived mutations may be filtered out by the 'hematopoietic filter' due to sequencing and PCR errors in the blood cell DNA.
